Anika Therapeutics (NSDQ:ANIK) said yesterday that regulatory authorities in Australia approved the company’s single injection viscosupplement, Monovisc, for the treatment of pain associated with osteoarthritis of the synovial joints.
This latest regulatory win means that Monovisc is commercially available in more than twenty countries, including the U.S. and Canada. The Bedford, Mass.-based company said it plans to move into additional international markets next year with its therapy for hip and knee pain.
“The Asia-Pacific region presents an important growth opportunity for our global orthobiologics franchise, and we’re excited to bring Monovisc to patients in Australia and New Zealand,” CEO Charles Sherwood said in prepared remarks. “With this approval, Monovisc is poised to become the most widely available single-injection viscosupplement in the world and will be a key driver in growing global market share.”
Anika has partnered exclusively with Surgical Specialties to market Monovisc in Australia and New Zealand, the company said.
In July, Anika named medtech veteran Joseph Darling as president, taking over the role fromSherwood. The chief exec plans to stay in the corner office as he transitions the role of president to Darling.
Previously, Darling worked as an executive in privately-held orthopedic companies. He has also held senior level executive roles at ConMed Corp. and Smith & Nephew.